Swoop

Life sciences brands are unique and seek to appeal to particular audiences of the overall patient population to drive awareness, prove value and increase consumption of their therapies. However, conventional marketing agencies, data providers and technology companies produce conventional off-the-shelf segments that fail to consider specific market definitions, target the same general patient profiles and inaccurately signal propensity. The result? An undifferentiated brand that broadly reaches too many or even the wrong potential patients who never end up actually engaging. Swoop is changing this.Swoop has developed the world’s first HIPAA-certified and NAI-accredited system of engagement that utilizes machine learning, artificial intelligence and granular-level longitudinal analysis in conjunction with an enriched and tokenized data pool of over 300 million de-identified patients to uncover precision target audiences of ideal patients that drive high performance omnichannel marketing campaigns so that pharmaceutical and biopharmaceutical companies can educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey.